STTR Phase I: Self-assembling molecular brachytherapy for treatment of metastatic cancer

STTR 第一期：自组装分子近距离放射治疗用于治疗转移性癌症

• 批准号: 2136700
• 负责人: Nicholas Trotta
• 金额: $ 25.57万
• 依托单位: Oncurie, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136700&HistoricalAwards=false
• 关键词: STTR; Phase; Self; assembling; molecular

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to enable radiotherapies for metastatic cancer, estimated to account for 90% of the 600,000 cancer deaths in the US each year. Of the approximately 1.8 million new cancer cases diagnosed each year in the US, nearly half are candidates for improved outcomes using some form of radiation-based therapy. Metastatic cancer, however, is generally not treated with radiotherapies due to the need for prior knowledge of the metastatic sites. The proposed project treats metastatic cancer by using the cancer cells themselves to help deliver the radiation. This technology may generate reliable efficacy of radiotherapy for the treatment of the most lethal forms of cancer.This Small Business Innovation Research Phase I project seeks to advance radiotherapy that exploits cancer cells themselves as catalysts for therapeutic delivery. After systemic administration or local injection, the monomers are expected to diffuse through tissues and subsequently polymerize, immobilizing radionuclides in the extracellular space of cancer cells. Non-cancerous cells will be minimally impacted, as soluble monomers will remain subject to diffusion and relatively rapid tissue clearance in the absence of cancer cell-derived catalysts. The chemistry at the core of the approach is an enzyme-triggered polymerization of native-like compounds under physiological conditions. The final therapeutic compound features the polymerizable compound and covalently-conjugated radionuclide 131-I, a commonly used radiotherapy isotope.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛影响/商业潜力是使转移性癌症的放射治疗成为可能，据估计，转移性癌症占美国每年60万癌症死亡人数的90%。在美国每年诊断的大约180万新癌症病例中，近一半是使用某种形式的放射治疗改善结果的候选人。然而，转移性癌症由于需要转移部位的先验知识而通常不用放射疗法治疗。拟议中的项目通过使用癌细胞本身来帮助提供辐射来治疗转移性癌症。这项技术可能会产生可靠的放射治疗效果，用于治疗最致命的癌症。这项小型企业创新研究第一阶段项目旨在推进放射治疗，利用癌细胞本身作为治疗传递的催化剂。在全身给药或局部注射后，预期单体通过组织扩散，随后将放射性核素固定在癌细胞的细胞外空间中。 非癌细胞将受到最小程度的影响，因为可溶性单体将在不存在癌细胞衍生的催化剂的情况下保持经受扩散和相对快速的组织清除。该方法的核心化学是在生理条件下天然化合物的酶触发聚合。 最终的治疗化合物的特点是可聚合化合物和共价共轭放射性核素131-I，一种常用的放射性同位素。该奖项反映了NSF的法定使命，并已被认为是值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估的支持。